NHS logo

Biosimilar Medicines

(Advice to NHSE) To what extent and how should the transition to use of biosimilar medicines be prioritised to enable the provision of best value care in the NHS? Does the clinical Senate support the update of biosimilar medicines at pace and how can their best practice use be maximised?

Clinical Senate

South West

Date:

Dec-17

Status:

Complete

Types of Work:

Advice